{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"135.300","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"921,143,176","primaryexch":"HKEX","ric":"9926.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BLFJ7Y1","am":"884.35","iv":"","ew_strike":"","as":"132.700","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"132.600","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-26 10:38:37.0","lo52":"54.000","shares_issued_date":"4 Sep 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Xia Yu","underlying_ric":"9926.HK","hi52":"179.000","issuer_name":"Akeso, Inc.","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"128.500","mkt_cap":"122.23","f_aum_hkd":null,"ew_sub_per_to":"","ls":"132.700","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-3.000","aum":"","issued_shares_class_B":null,"vo":"6.67","secondary_listing_flag":false,"listing_date":"24 Apr 2020","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Akeso, Inc.","nm_s":"AKESO","sym":"9926","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.100","strike_price":"","summary":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Companyâ€™s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","op":"132.100","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Room 1901, 19/F<br/>Lee Garden One<br/>33 Hysan Avenue<br/>Causeway Bay, Hong Kong","pc":"-2.21","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"135.700","isin":"KYG0146B1032","moneyness":""}},"qid":"1758889980870"}
